USPTO Examiner STRZELECKA TERESA E - Art Unit 1637

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
17139127COMPOSITIONS AND METHODS FOR NUCLEIC ACID AMPLIFICATIONDecember 2020July 2023Allow3121NoNo
17135878METHODS FOR AMPLIFYING NUCLEIC ACID USING TAG-MEDIATED DISPLACEMENTDecember 2020July 2023Allow3111NoNo
17122055PRIMER, KIT AND METHOD FOR DETECTING TAIHE BLACK CHICKEN EGGDecember 2020February 2023Abandon2610NoNo
17093298MULTIPLEXED OPTIMIZED MISMATCH AMPLIFICATION (MOMA)-CANCER RISK ASSESSMENT WITH NON-CANCER ASSOCIATED TARGETSNovember 2020December 2023Abandon3701NoNo
17091639USING RANDOM PRIMING TO OBTAIN FULL-LENGTH V(D)J INFORMATION FOR IMMUNE REPERTOIRE SEQUENCINGNovember 2020March 2023Allow2811NoNo
17083803METHOD FOR PREIMPLANTATION GENETIC SCREENING OF EMBRYOS FOR DETECTION OF STRUCTURAL REARRANGEMENTSOctober 2020June 2023Allow3220NoNo
17079268METHODS FOR 3' OVERHANG REPAIROctober 2020June 2022Allow2000NoNo
17078463HIGHLY SELECTIVE NUCLEIC ACID AMPLIFICATION PRIMERSOctober 2020June 2021Allow810NoNo
16949159METHODS AND COMPOSITIONS FOR MULTIPLEX PCROctober 2020August 2023Allow3421NoNo
17070707Method for Synthesizing Nucleic Acids, in particular Long Nucleic Acids, Use of Said Method and Kit for Implementing Said MethodOctober 2020March 2023Allow2910NoNo
17064508METHODS AND COMPOSITIONS FOR TARGETED NUCLEIC ACID SEQUENCINGOctober 2020March 2023Allow3010NoNo
17024225METHOD AND DEVICE FOR TESTING TARGET NUCLEIC ACIDSeptember 2020April 2023Allow3111NoNo
17019109METHODS AND COMPOSITIONS FOR PROTEIN AND PEPTIDE SEQUENCINGSeptember 2020April 2023Allow3111NoNo
17014540CANCER-RELATED BIOLOGICAL MATERIALS IN MICROVESICLESSeptember 2020May 2023Abandon3210NoNo
17002321Method of detecting genetic material in a biological sample and a device for its implementationAugust 2020January 2023Allow2910NoNo
16990000PRIMER SET FOR PCR FOR BACTERIAL DNA AMPLIFICATION, KIT FOR DETECTION AND/OR IDENTIFICATION OF BACTERIAL SPECIES, AND, METHOD OF DETECTION AND/OR IDENTIFICATION OF BACTERIAL SPECIESAugust 2020December 2023Abandon4030NoNo
16986066METHODS AND COMPOSITIONS FOR WHOLE GENOME AMPLIFICATION AND GENOTYPINGAugust 2020October 2022Allow2710NoNo
16983947SEQUENCING FROM MULTIPLE PRIMERS TO INCREASE DATA RATE AND DENSITYAugust 2020June 2022Allow2200NoNo
16945173METHODS FOR SEQUENCING WITH SINGLE FREQUENCY DETECTIONJuly 2020October 2022Allow2711NoNo
16934799METHOD AND KIT FOR DETERMINING NEUROMUSCULAR DISEASE IN SUBJECTJuly 2020February 2023Abandon3101NoNo
16917185FETAL ANEUPLOIDY DETECTION BY SEQUENCINGJune 2020January 2023Allow3120NoNo
16908822METHODS FOR SCREENING A SUBJECT FOR A CANCERJune 2020July 2023Allow3721YesNo
16908572LEUKEMIA METHYLATION MARKERS AND USES THEREOFJune 2020January 2023Abandon3101NoNo
16908567OLIGONUCLEOTIDE-TETHERED NUCLEOTIDESJune 2020March 2023Allow3311NoNo
16906115TM MAPPING METHODJune 2020March 2023Allow3320NoNo
16898897BLOOD DNA METHYLATION BIOMARKER DIAGNOSTIC TEST FOR ANXIETY AND DEPRESSIVE DISORDERSJune 2020August 2022Allow2601NoNo
16891018METHOD FOR PRODUCING RNAJune 2020October 2021Allow1711NoNo
16768802RAPID NUCLEIC ACIDS SEPARATION AND SAMPLE PREPARATION VIA HOLLOW-CENTERED SILICA MICROSPHEREJune 2020July 2022Allow2621NoNo
16768627PCR CONTROLSMay 2020August 2022Allow2710NoNo
16764642METHODS AND KITS FOR USING RECOMBINANT MICROORGANISMS AS DIRECT REAGENTS IN BIOLOGICAL APPLICATIONSMay 2020June 2023Allow3731NoNo
15930488SAMPLE PREPARATION METHODS, SYSTEMS AND COMPOSITIONSMay 2020July 2021Allow1411YesNo
16761458METHODS AND KITS FOR TARGETED ENRICHMENT OF TARGET DNA WITH HIGH GC CONTENTMay 2020April 2022Allow2410NoNo
16864408METHODS USING RANDOMER-CONTAINING SYNTHETIC MOLECULESMay 2020September 2021Allow1700NoNo
16862637Biomarkers in Peripheral Blood Mononuclear Cells for Diagnosing or Detecting Lung CancersApril 2020March 2023Abandon3401NoNo
16758873Methods for preparing RNA probes for exome sequencing and for depleting organelle DNAApril 2020January 2023Abandon3301NoNo
16755829NEW TOOLS FOR ASSESSING FIMH BLOCKERS THERAPEUTIC EFFICIENCYApril 2020September 2023Allow4121YesNo
16755190METHOD FOR DIAGNOSING ALZHEIMER DEMENTIA VIA BACTERIAL METAGENOMIC ANALYSISApril 2020September 2023Abandon4221NoNo
16845472DIRECT AMPLIFICATION AND DETECTION OF VIRAL AND BACTERIAL PATHOGENSApril 2020August 2023Allow4052NoNo
16840168ANALYSIS OF Y-CHROMOSOME STR MARKERSApril 2020May 2022Allow2541NoNo
16834141DEGENERATE OLIGONUCLEOTIDES AND THEIR USESMarch 2020August 2021Abandon1710NoNo
16651940ANALYSIS METHOD FOR EXTRACELLULAR VESICLES, USING SIZE EXCLUSION CHROMATOGRAPHY, AND USE FOR SAMEMarch 2020July 2023Allow3911NoNo
16819992DIAGNOSIS OF FETAL ABNORMALITIES USING POLYMORPHISMS INCLUDING SHORT TANDEM REPEATSMarch 2020February 2022Allow2311NoNo
16816481Methods for Microbial DNA AnalysisMarch 2020February 2022Allow2341NoNo
16800450DETECTION OF SEQUENCE ELEMENTS IN NUCLEIC ACID MOLECULESFebruary 2020January 2023Allow3411YesNo
16795388NANOPORE-BASED POLYMER ANALYSIS WITH MUTUALLY-QUENCHING FLUORESCENT LABELSFebruary 2020May 2022Abandon2720NoYes
16793680COMPOSITIONS AND METHODS FOR LABELING OF AGENTSFebruary 2020August 2022Abandon3021NoYes
16790283METHODS AND KITS FOR REDUCING ADAPTER-DIMER FORMATIONFebruary 2020May 2022Abandon2730NoNo
16785837MOLECULAR ASSAY METHODSFebruary 2020January 2021Allow1200NoNo
16786198METHOD FOR SELECTING AND AMPLIFYING POLYNUCLEOTIDESFebruary 2020August 2021Allow1821NoNo
16773539METHODS AND COMPOSITIONS FOR GENERATING ASYMMETRICALLY-TAGGED NUCLEIC ACID FRAGMENTSJanuary 2020March 2021Allow1411NoNo
16746216COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDSJanuary 2020September 2021Allow2021NoNo
16743604COMPOSITIONS AND METHODS FOR IDENTIFICATION OF A DUPLICATE SEQUENCING READJanuary 2020April 2021Allow1510NoNo
16631324EML4-ALK GENE MUTATION ANALYSIS METHODJanuary 2020May 2023Allow4031YesNo
16726034MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCERDecember 2019December 2021Abandon2411NoNo
16625437TARGET-ENRICHED MULTIPLEXED PARALLEL ANALYSIS FOR ASSESSMENT OF FETAL DNA SAMPLESDecember 2019January 2023Allow3620YesNo
16720823EFFICIENT METHODS AND COMPOSITIONS FOR MULTIPLEX TARGET AMPLIFICATION PCRDecember 2019March 2023Allow3911NoNo
16623707ASSESSING TRANSPLANT COMPLICATION RISK WITH TOTAL CELL-FREE DNADecember 2019March 2023Allow3921NoNo
16622059DIAGNOSTIC, PROGNOSTIC AND THERAPEUTIC USES OF LONG NONCODING RNAs FOR PATHOLOGIES AND TOXICITIES INDUCING HEART DISORDERSDecember 2019December 2022Allow3621NoNo
16619945TWO MOLECULAR MARKERS, KITS AND APPLICATIONS FOR GLAUCOMA DIAGNOSISDecember 2019June 2023Abandon4221NoNo
16616735ARRAY-BASED METHODS FOR ANALYSING MIXED SAMPLES USING DIFFERENTLY LABELLED ALLELE-SPECIFIC PROBESNovember 2019September 2022Allow3311NoNo
16616741ARRAY-BASED METHODS FOR ANALYSING MIXED SAMPLES USING DIFFERENTLY LABELLED ALLELE-SPECIFIC PROBESNovember 2019April 2022Allow2910NoNo
16616725ARRAY-BASED METHODS FOR ANALYSING MIXED SAMPLES USING DIFFERENT ALLELE-SPECIFIC LABELS, IN PARTICULAR FOR DETECTION OF FETAL ANEUPLOIDIESNovember 2019August 2022Allow3320NoNo
16616532OLIGONUCLEOTIDE PRESERVATION METHODNovember 2019October 2022Allow3520NoNo
16616134SINGLE MOLECULE DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS WITH SINGLE BASE SPECIFICITYNovember 2019December 2022Abandon3720NoNo
16606944METHOD FOR REMOVING NON-TARGET RNA FROM RNA SAMPLEOctober 2019February 2022Allow2710NoNo
16597877Kits and Methods for Detecting Methylated DNAOctober 2019December 2021Abandon2621NoNo
16577491CIRCULATING MICRORNA AS A MARKER FOR HEPATOCELLULAR CARCINOMASeptember 2019April 2022Allow3131NoNo
16495721PROGRAMMABLE NUCLEIC ACID SYNTHESIS CASCADESeptember 2019July 2021Allow2201YesNo
16494121METHOD FOR DETECTING TARGET MOLECULE IN WHICH ROLLING CIRCLE AMPLIFICATION IS USEDSeptember 2019March 2022Allow3010NoNo
16570873METHOD AND SYSTEM FOR SEQUENCING NUCLEIC ACIDSSeptember 2019July 2021Allow2221NoNo
16564948TEST FOR DETECTING ALZHEIMERS DISEASESeptember 2019March 2022Allow3110NoNo
16481964METHODS AND COMPOSITIONS RELATING TO DETECTION OF RECOMBINATION AND REARRANGEMENT EVENTSJuly 2019September 2023Abandon5040NoNo
16525826METHODS AND SYSTEMS FOR NUCLEIC ACID SEQUENCINGJuly 2019January 2023Allow4111YesNo
16480535COMPOSITIONS AND METHODS FOR DETECTING A MUTANT VARIANT OF A POLYNUCLEOTIDEJuly 2019September 2022Allow3720NoNo
16518321SERIAL FORMATION OF TERNARY COMPLEX SPECIESJuly 2019May 2022Allow3421YesNo
16478705METHODS OF RNA AMPLIFICATIONJuly 2019September 2021Allow2610NoNo
16477794RAPID ANTIMICROBIAL SUSCEPTIBILITY TESTING AND PHYLOGENETIC IDENTIFICATIONJuly 2019March 2022Abandon3201NoNo
16505496POLYMERASE-TEMPLATE COMPLEXESJuly 2019February 2021Allow1911NoNo
16476256PCR MEASURING METHOD AND MEASUREMENT DEVICEJuly 2019September 2023Allow5051YesNo
16503262METHODS, SYSTEMS, COMPOSITIONS, KITS, APPARATUS AND COMPUTER-READABLE MEDIA FOR MOLECULAR TAGGINGJuly 2019April 2021Allow2121NoNo
16460647DETECTION OF NEOPLASIA BY ANALYSIS OF METHYLATED DNAJuly 2019February 2021Allow1911YesNo
16433621MULTIPLEXED CATALYZED REPORTER DEPOSITIONJune 2019January 2023Allow4411NoNo
16464284METHOD AND BIOMARKERS FOR IN VITRO DIAGNOSIS OF MENTAL DISORDERSMay 2019March 2022Abandon3311NoNo
16422056Polyphenolic Additives in Sequencing by SynthesisMay 2019March 2021Allow2210NoNo
16417817SAFE SEQUENCING SYSTEMMay 2019April 2021Allow2310NoNo
16414705MULTI-PRIMER AMPLIFICATION METHOD FOR TAGGING OF TARGET NUCLEIC ACIDSMay 2019April 2021Abandon2310NoNo
16408302METHODS AND COMPOSITIONS FOR GENERATING ASYMMETRICALLY-TAGGED NUCLEIC ACID FRAGMENTSMay 2019October 2019Allow600YesNo
16347185METHODS FOR ASSESSING RISK USING MISMATCH AMPLIFICATION AND STATISTICAL METHODSMay 2019June 2022Abandon3701NoNo
16399941DETECTING MUTATIONS AND PLOIDY IN CHROMOSOMAL SEGMENTSApril 2019September 2021Abandon2941NoNo
16392114METHODS AND COMPOSITIONS FOR ENRICHMENT OF TARGET NUCLEIC ACIDSApril 2019October 2021Allow3001NoNo
16389596Computational Method for Detecting Fusion EventsApril 2019September 2021Allow2920YesNo
16389584Highly Multiplexed Polymerase Chain ReactionApril 2019June 2021Abandon2610NoNo
16389573Multiplexed Gene Fusion Detection MethodApril 2019March 2021Abandon2311NoNo
16389588Detection of Fusion Events Using Replicate PCR ReactionsApril 2019July 2021Abandon2710NoNo
16389565Method for Detecting a Genomic Fusion EventApril 2019April 2021Abandon2410NoNo
16386729SINGLE REACTION MULTIPLEX PCR PRIMER DESIGN FOR AMPLIFYING MULTIPLE HLA CLASS I AND II GENESApril 2019December 2022Allow4432NoNo
16342722UNIMOLECULAR APTAMER-BASED SENSORS FOR PATHOGEN DETECTIONApril 2019May 2023Allow4911NoNo
16327754METHOD FOR INSERTING DESIRED DNA FRAGMENT INTO SITE LOCATED ADJACENT TO BINDING DOMAIN OF DNA-BINDING PROTEINApril 2019June 2022Allow3910NoNo
16385970Methods for Treating and Detecting Johne's Disease in CattleApril 2019November 2021Abandon3101NoNo
16384262PRIMERS, COMPOSITIONS, AND METHODS FOR NUCLEIC ACID SEQUENCE VARIATION DETECTIONApril 2019February 2022Allow3430NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STRZELECKA, TERESA E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
15
Examiner Affirmed
13
(86.7%)
Examiner Reversed
2
(13.3%)
Reversal Percentile
25.6%
Lower than average

What This Means

With a 13.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
109
Allowed After Appeal Filing
15
(13.8%)
Not Allowed After Appeal Filing
94
(86.2%)
Filing Benefit Percentile
17.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 13.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner STRZELECKA, TERESA E - Prosecution Strategy Guide

Executive Summary

Examiner STRZELECKA, TERESA E works in Art Unit 1637 and has examined 1,132 patent applications in our dataset. With an allowance rate of 49.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner STRZELECKA, TERESA E's allowance rate of 49.5% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by STRZELECKA, TERESA E receive 2.20 office actions before reaching final disposition. This places the examiner in the 56% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by STRZELECKA, TERESA E is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +35.8% benefit to allowance rate for applications examined by STRZELECKA, TERESA E. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.5% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 40.3% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 90.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 72.2% of appeals filed. This is in the 60% percentile among all examiners. Of these withdrawals, 87.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 59.7% are granted (fully or in part). This grant rate is in the 61% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 5.7% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.6% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.